A61K31/537

COMPOSITIONS AND METHODS FOR TREATING VASCULAR EHLERS DANLOS SYNDROME AND ASSOCIATED DISORDERS

The present invention relates to compositions and methods for treating vascular Ehlers Danlos Syndrome and associated connective tissue disorders.

COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR
20220204640 · 2022-06-30 · ·

The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.

COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR
20220204640 · 2022-06-30 · ·

The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.

Anti-CEACAM5 antibodies and uses thereof

Disclosed are antibodies which bind human and Macaca fascicularis CEACAM5 proteins, as well as isolated nucleic acids, vectors and host cells comprising a sequence encoding the antibodies. Also disclosed are immunoconjugates comprising the antibodies conjugated or linked to a growth-inhibitory agent, and pharmaceutical compositions comprising the antibodies or immunoconjugates of the invention. The antibodies or immunoconjugates are used for the treatment of cancer or for diagnostic purposes.

Anti-CEACAM5 antibodies and uses thereof

Disclosed are antibodies which bind human and Macaca fascicularis CEACAM5 proteins, as well as isolated nucleic acids, vectors and host cells comprising a sequence encoding the antibodies. Also disclosed are immunoconjugates comprising the antibodies conjugated or linked to a growth-inhibitory agent, and pharmaceutical compositions comprising the antibodies or immunoconjugates of the invention. The antibodies or immunoconjugates are used for the treatment of cancer or for diagnostic purposes.

BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR CD38

The present invention relates to polypeptides which are covalently bound to aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of CD38. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by CD38.

BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR CD38

The present invention relates to polypeptides which are covalently bound to aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of CD38. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by CD38.

HIV protease inhibitors
11318119 · 2022-05-03 · ·

The present disclosure provides compounds, or a pharmaceutically acceptable salt thereof as described herein, useful for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS symptoms in a subject. The disclosure also provides pharmaceutical compositions comprising these compounds, processes for preparing them, therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS symptoms in a subject using these compounds. The present disclosure also provides compounds, or a pharmaceutically acceptable salt thereof as described herein, useful for treating the proliferation of a coronavirus, treating coronavirus symptoms or delaying the onset of coronavirus symptoms in a subject. The disclosure also provides pharmaceutical compositions comprising these compounds, processes for preparing them, therapeutic methods for treating the proliferation of a coronavirus, treating coronavirus symptoms or delaying the onset of coronavirus symptoms in a subject using these compounds.

HIV protease inhibitors
11318119 · 2022-05-03 · ·

The present disclosure provides compounds, or a pharmaceutically acceptable salt thereof as described herein, useful for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS symptoms in a subject. The disclosure also provides pharmaceutical compositions comprising these compounds, processes for preparing them, therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS symptoms in a subject using these compounds. The present disclosure also provides compounds, or a pharmaceutically acceptable salt thereof as described herein, useful for treating the proliferation of a coronavirus, treating coronavirus symptoms or delaying the onset of coronavirus symptoms in a subject. The disclosure also provides pharmaceutical compositions comprising these compounds, processes for preparing them, therapeutic methods for treating the proliferation of a coronavirus, treating coronavirus symptoms or delaying the onset of coronavirus symptoms in a subject using these compounds.

BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR CAIX

The present invention relates to polypeptides which are covalently bound to aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of carbonic anhydrase IX (CAIX).The invention also includes dmg conjugates comprising said peptides,conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by CAIX.